MiR-155-5p Elevated by Ochratoxin A Induces Intestinal Fibrosis and Epithelial-to-Mesenchymal Transition Through TGF-β Regulated Signaling Pathway In Vitro and In Vivo

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2023 Jul 28

PMID 37505742

Authors

Kyu Hyun Rhee

Seon Ah Yang

Min Cheol Pyo

Jae-Min Lim

Kwang-Won Lee

Affiliations

Soon will be listed here.

Abstract

Ochratoxin A (OTA) is a mycotoxin that induces fibrosis and epithelial-to-mesenchymal transitions (EMT) in kidneys and livers. It enters our bodies through food consumption, where it is absorbed in the intestines. However, the impact of OTA on the intestines is yet to be studied. MicroRNA (miRNAs) are small non-coding single-stranded RNAs that block the transcription of specific mRNAs and are, therefore, involved in many biochemical processes. Our findings indicate that OTA can induce EMT and intestinal fibrosis both in vivo and in vitro. This study examines the impact of OTA on intestinal toxicity and the role of miRNAs in this process. Following OTA treatment, miR-155-5p was the most elevated miRNA by next-generation sequencing. Our research showed that OTA increased miR-155-5p levels through transforming growth factor β (TGF-β), leading to the development of intestinal fibrosis and EMT. Additionally, the study identified that the modulation of TGF-β and miR-155-5p by OTA is linked to the inhibition of CCAAT/enhancer-binding protein β (C/EBPβ) and Smad2/3 accumulation in the progression of intestinal fibrosis.

Citing Articles

Early Biomarkers for Detecting Subclinical Exposure to Fumonisin B1, Deoxynivalenol, and Zearalenone in Broiler Chickens.

Kappari L, Applegate T, Glenn A, Bakre A, Shanmugasundaram R Toxins (Basel). 2025; 17(1).

PMID: 39852954 PMC: 11769279. DOI: 10.3390/toxins17010001.

Effect of atractylenolide III on zearalenone-induced Snail1-mediated epithelial-mesenchymal transition in porcine intestinal epithelium.

Kim N, Kim M, Shin S, Kwon W, Kim B, Lee J J Anim Sci Biotechnol. 2024; 15(1):80.

PMID: 38845033 PMC: 11157892. DOI: 10.1186/s40104-024-01038-z.

MicroRNAs: exploring their role in farm animal disease and mycotoxin challenges.

Kappari L, Dasireddy J, Applegate T, Selvaraj R, Shanmugasundaram R Front Vet Sci. 2024; 11:1372961.

PMID: 38803799 PMC: 11129562. DOI: 10.3389/fvets.2024.1372961.

Comprehensive Insights into Ochratoxin A: Occurrence, Analysis, and Control Strategies.

Ben Miri Y, Benabdallah A, Chentir I, Djenane D, Luvisi A, De Bellis L Foods. 2024; 13(8).

PMID: 38672856 PMC: 11049263. DOI: 10.3390/foods13081184.

Preventing fibrosis in IBD: update on immune pathways and clinical strategies.

Wang J, Yang B, Chandra J, Ivanov A, Brown J, Rieder F Expert Rev Clin Immunol. 2024; 20(7):727-734.

PMID: 38475672 PMC: 11180587. DOI: 10.1080/1744666X.2024.2330604.

References

Zhang W, Li X, Tang Y, Chen C, Jing R, Liu T . miR-155-5p Implicates in the Pathogenesis of Renal Fibrosis via Targeting SOCS1 and SOCS6. Oxid Med Cell Longev. 2020; 2020:6263921. PMC: 7298347. DOI: 10.1155/2020/6263921. View

Johansson J, Berg T, Kurzejamska E, Pang M, Tabor V, Jansson M . MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene. 2013; 32(50):5614-24. PMC: 3898103. DOI: 10.1038/onc.2013.322. View

Yun S, Kim S, Kim E . The Molecular Mechanism of Transforming Growth Factor-β Signaling for Intestinal Fibrosis: A Mini-Review. Front Pharmacol. 2019; 10:162. PMC: 6400889. DOI: 10.3389/fphar.2019.00162. View

Beres N, Kiss Z, Sztupinszki Z, Lendvai G, Arato A, Sziksz E . Altered mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease. Dig Liver Dis. 2017; 49(4):378-387. DOI: 10.1016/j.dld.2016.12.022. View

Speca S, Giusti I, Rieder F, Latella G . Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol. 2012; 18(28):3635-61. PMC: 3406417. DOI: 10.3748/wjg.v18.i28.3635. View

Kim S, Jeong Y, Pyo M, Lee K . Combined effects of cadmium and ochratoxin A on intestinal barrier dysfunction in human Caco-2 cells and pig small intestinal epithelial cells. Mycotoxin Res. 2022; 38(4):253-264. DOI: 10.1007/s12550-022-00464-0. View

Xia D, Yang L, Li Y, Chen J, Zhang X, Wang H . Melatonin alleviates Ochratoxin A-induced liver inflammation involved intestinal microbiota homeostasis and microbiota-independent manner. J Hazard Mater. 2021; 413:125239. DOI: 10.1016/j.jhazmat.2021.125239. View

OBrien J, Hayder H, Zayed Y, Peng C . Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018; 9:402. PMC: 6085463. DOI: 10.3389/fendo.2018.00402. View

Schaaf G, Nijmeijer S, Maas R, Roestenberg P, de Groene E, Fink-Gremmels J . The role of oxidative stress in the ochratoxin A-mediated toxicity in proximal tubular cells. Biochim Biophys Acta. 2002; 1588(2):149-58. DOI: 10.1016/s0925-4439(02)00159-x. View

10.

Clark H, Snedeker S . Ochratoxin a: its cancer risk and potential for exposure. J Toxicol Environ Health B Crit Rev. 2006; 9(3):265-96. DOI: 10.1080/15287390500195570. View

11.

Deng H, Chen W, Zhang B, Zhang Y, Han L, Zhang Q . Excessive ER-phagy contributes to ochratoxin A-induced apoptosis. Food Chem Toxicol. 2023; 176:113793. DOI: 10.1016/j.fct.2023.113793. View

12.

Gao Y, Li S, Wang J, Luo C, Zhao S, Zheng N . Modulation of Intestinal Epithelial Permeability in Differentiated Caco-2 Cells Exposed to Aflatoxin M1 and Ochratoxin A Individually or Collectively. Toxins (Basel). 2017; 10(1). PMC: 5793100. DOI: 10.3390/toxins10010013. View

13.

Roderburg C, Urban G, Bettermann K, Vucur M, Zimmermann H, Schmidt S . Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2010; 53(1):209-18. DOI: 10.1002/hep.23922. View

14.

Pyo M, Choi I, Lee K . Transcriptome Analysis Reveals the AhR, Smad2/3, and HIF-1α Pathways as the Mechanism of Ochratoxin A Toxicity in Kidney Cells. Toxins (Basel). 2021; 13(3). PMC: 7999264. DOI: 10.3390/toxins13030190. View

15.

Lewis A, Nijhuis A, Mehta S, Kumagai T, Feakins R, Lindsay J . Intestinal fibrosis in Crohn's disease: role of microRNAs as fibrogenic modulators, serum biomarkers, and therapeutic targets. Inflamm Bowel Dis. 2015; 21(5):1141-50. DOI: 10.1097/MIB.0000000000000298. View

16.

Pyo M, Chae S, Yoo H, Lee K . Ochratoxin A induces epithelial-to-mesenchymal transition and renal fibrosis through TGF-β/Smad2/3 and Wnt1/β-catenin signaling pathways in vitro and in vivo. Arch Toxicol. 2020; 94(9):3329-3342. DOI: 10.1007/s00204-020-02829-9. View

17.

Ying S, Chang D, Lin S . The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol. 2007; 38(3):257-68. PMC: 7091389. DOI: 10.1007/s12033-007-9013-8. View

18.

Hibi D, Kijima A, Suzuki Y, Ishii Y, Jin M, Sugita-Konishi Y . Effects of p53 knockout on ochratoxin A-induced genotoxicity in p53-deficient gpt delta mice. Toxicology. 2012; 304:92-9. DOI: 10.1016/j.tox.2012.12.005. View

19.

OReilly S . MicroRNAs in fibrosis: opportunities and challenges. Arthritis Res Ther. 2016; 18:11. PMC: 4718015. DOI: 10.1186/s13075-016-0929-x. View

20.

Yang S, Lee S, Pyo M, Jeon H, Kim Y, Lee K . Improved physicochemical properties and hepatic protection of Maillard reaction products derived from fish protein hydrolysates and ribose. Food Chem. 2016; 221:1979-1988. DOI: 10.1016/j.foodchem.2016.11.145. View